Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fegan

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Leukemia|August 11, 2015
Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trialJ C Strefford, L Kadalayil, J Forster, et al.
Leukemia|January 22, 2010
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemiaJ M Allan, N J Sunter, J R Bailey, et al.
Leukemia|November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia riskG P Sava, H E Speedy, M C Di Bernardo, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Leukemia|August 11, 2015
Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trialJ C Strefford, L Kadalayil, J Forster, et al.
Leukemia|January 22, 2010
Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemiaJ M Allan, N J Sunter, J R Bailey, et al.
Leukemia|November 4, 2014
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia riskG P Sava, H E Speedy, M C Di Bernardo, et al.
Pageof 5